Clinical Trials Logo

Clinical Trial Summary

This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in multiple parts to establish the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile (with and without food) and early signs of efficacy of Tuvuseritib (M1774) as monotherapy and in combination with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Metastatic or Locally Advanced Unresectable Solid Tumors
  • Neoplasms

NCT number NCT04170153
Study type Interventional
Source EMD Serono
Contact
Status Active, not recruiting
Phase Phase 1
Start date December 20, 2019
Completion date January 30, 2025

See also
  Status Clinical Trial Phase
Terminated NCT03306420 - First-in-Human Study of MS201408-0005A as Single Agent and in Combinations Phase 1
Terminated NCT05198349 - First in Human Study of M1069 in Advanced Solid Tumors Phase 1
Recruiting NCT05396833 - Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) Phase 1